StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Zopiclon

Zopiclone

HCID 5735
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
43200-80-2
Standard-SMILES
CN1CCN(C(=O)OC2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1
InChIKey
GBBSUAFBMRNDJC-UHFFFAOYSA-N
Summenformel
C17H17ClN6O3
Durchschnittliche Molmasse
388,8 g/mol
Monoisotopische Masse
388,10506608

Überblick

Zopiclone is a pyrrolo[3,4-b]pyrazine compound having a 4-methylpiperazine-1-carboxyl group at the 5-position, a 5-chloropyridin-2-yl group at the 6-position and an oxo-substituent at the 7-position. It has a role as a central nervous system depressant and a sedative. It is a monochloropyridine and a pyrrolopyrazine.

Namen und Bezeichner

Bevorzugter Name
Zopiclone
IUPAC
[6-(5-chloro-2-pyridinyl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylate
Lokaler Name
Zopiclon
Englischer Name
Zopiclone
Summenformel
C17H17ClN6O3
Molmasse
388.81

Namen und Synonyme

zopiclone43200-80-2ImovaneAmobanZimovane(+-)-ZopicloneZopiclonaZopiclonumXimovanRP-27267[6-(5-chloropyridin-2-yl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylateRP 27267
Weitere Namen anzeigen
Zopiclone R-IsoMer CIV6-(5-Chloro-2-pyridinyl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methyl-1-piperazinecarboxylateImobamLimovanAmovaneSopivanCS-1331
Zimovane LSNSC-75846303A5ORL08QZileze 7.5CHEBI:32315Zileze 3.751-Piperazinecarboxylic acid, 4-methyl-, 6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo(3,4-b)pyrazin-5-yl esterDTXSID4041155

Datenbank-Bezeichner

CAS
43200-80-2
PubChem CID
5735
DTXSID
DTXSID4041155

Eigenschaften

Berechnete Struktureigenschaften

XLogP
0,5
Polarare Oberfläche (TPSA)
91,8 Ų
H-Brücken-Donoren
0
H-Brücken-Akzeptoren
7
Frei drehbare Bindungen
3
Schwere Atome
27
Formalladung
0
Komplexität
573

Experimentelle und physikochemische Eigenschaften

Drugs · 5 Einträge

DEA NFLIS-Drug Category -> Depressants and Tranquilizers

DEA Schedule IV Controlled Substance -> Depressants

Pharmaceuticals -> Hypnotic

Pharmaceuticals -> Synthetic Cannabinoids or Psychoactive Compounds

Pharmaceuticals

LogP · 2 Einträge

0.8

1.1

Solubility · 2 Einträge

8.85e-01 g/L

>58.3 [ug/mL] (The mean of the results at pH 7.4)

Human DrugsPharmaceuticals
Melting Point178 °C
Physical DescriptionSolid
Collision Cross Section · 3 Einträge

188.5 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

186.5 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

176.57 Ų [M+H-H2O]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Warning

H302+H312+H332 (20.1%): Harmful if swallowed, in contact with skin or if inhaled [Warning Acute toxicity, oral; acute toxicity, dermal; acute toxicity, inhalation]

P203, P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P317, P318, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 139 reports by companies from 19 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Regulatory Information · 2 Einträge

DEA schedule IV controlled substance

Zopiclone: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.

Hazard Classes and CategoriesAcute Tox. 4 (100%)

Toxikologische Informationen

Health EffectsThey cause slurred speech, disorientation and "drunken" behavior. They are physically and psychologically addictive.
Exposure RoutesRapidly absorbed following oral administration.
Toxicity Summary · 1 Eintrag

Zopiclone exerts its action by binding on the benzodiazepine receptor complex and modulation of the GABA<sub>B</sub>Z receptor chloride channel macromolecular complex. Both zopiclone and benzodiazepines act indiscriminately at the benzodiazepine binding site on alpha1, alpha2, alpha3 and alpha5 GABAA containing receptors as full agonists causing an enhancement of the inhibitory actions of GABA to produce the therapeutic (hypnotic and anxiolytic) and adverse effects of zopiclone.

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 3 Einträge

N05CF01

N - Nervous system

QN - Nervous system

Protein BindingApproximately 45%
Pharmacodynamics · 1 Eintrag

Zopiclone is a nonbenzodiazepine hypnotic from the pyrazolopyrimidine class and is indicated for the short-term treatment of insomnia. While Zopiclone is a hypnotic agent with a chemical structure unrelated to benzodiazepines, barbiturates, or other drugs with known hypnotic properties, it interacts with the gamma-aminobutyric acid-benzodiazepine (GABA<sub>B</sub>Z) receptor complex. Subunit modulation of the GABA<sub>B</sub>Z receptor chloride channel macromolecular complex is hypothesized to be responsible for some of the pharmacological properties of benzodiazepines, which include sedative, anxiolytic, muscle relaxant, and anticonvulsive effects in animal models. Zopiclone binds selectively to the brain alpha subunit of the GABA A omega-1 receptor.

Mechanism of Action · 1 Eintrag

Zopiclone exerts its action by binding on the benzodiazepine receptor complex and modulation of the GABA<sub>B</sub>Z receptor chloride channel macromolecular complex. Both zopiclone and benzodiazepines act indiscriminately at the benzodiazepine binding site on α1, α2, α3 and α5 GABAA containing receptors as full agonists causing an enhancement of the inhibitory actions of GABA to produce the therapeutic (hypnotic and anxiolytic) and adverse effects of zopiclone.

Biological Half-LifeElimination half life is approximately 5 hours (range 3.8 to 6.5 hours) and is prolonged to 11.9 hours in patients with hepatic insufficiency.
Metabolism/Metabolites · 2 Einträge

Extensively metabolized in the liver via decarboxylation (major pathway), demethylation, and side chain oxidation. Metabolites include an N-oxide derivative (weakly active; approximately 12% of a dose) and an N-desmethyl metabolite (inactive; approximately 16%). Approximately 50% of a dose is converted to other inactive metabolites via decarboxylation. Hepatic microsomal enzymes are apparently not involved in zopiclone clearance.

Zugehörige Reaktionen

16
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 44214
HRID 44214als Edukt
Reaktionsgleichung von HRID 113635
HRID 113635als Edukt
Reaktionsgleichung von HRID 217643
HRID 217643als Edukt
Reaktionsgleichung von HRID 217645
HRID 217645als Edukt
Reaktionsgleichung von HRID 336391
HRID 336391als Edukt
Reaktionsgleichung von HRID 454829
HRID 454829als Edukt
Reaktionsgleichung von HRID 507798
HRID 507798als Edukt
Reaktionsgleichung von HRID 507800
HRID 507800als Produkt
ZurückSeite 1 von 2

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
ChEMBL
CHEMBL135400
ChEBI
CHEBI:32315
UNII
03A5ORL08Q
EC Number
256-138-9
Nikkaji
J16.885H

Physikochemische Eigenschaften

Schmelzpunkt
1780 C · 1780C
Siedepunkt
580.7 · 580.7±50.0 °C(Predicted)
Dichte
1.1105 · 1.1105 (estimate)
Flammpunkt
2 ℃ · 2℃
storage temp.
Store at RT
Löslichkeit
2 mg/mL · DMSO: 2 mg/mL
pka
1.5 · pKa ﹣1.5±0.1(10% ACN in aq. H2SO4 t = 25.0) (Uncertain)
Aggregatzustand
Solid
Farbe
White to Off-White
Stabilität
Hygroscopic
Major Application
clinical testing
InChI
1S/C17H17ClN6O3/c1-22-6-8-23(9-7-22)17(26)27-16-14-13(19-4-5-20-14)15(25)24(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3/p+1
InChIKey
GBBSUAFBMRNDJC-UHFFFAOYSA-N
SMILES
C[NH+]1CCN(CC1)C(=O)OC2N(C(=O)c3nccnc23)c4ccc(Cl)cn4
CAS Datenbank
43200 · 43200-80-2(CAS DataBase Reference)
NIST chemische Informationen
Zopiclone(43200-80-2)
Signs and Symptoms · 1 Eintrag

Rare individual instances of fatal outcomes following overdose with racemic zopiclone have been reported in European postmarketing reports, most often associated with overdose with other CNS-depressant agent. Signs and symptoms of overdose effects of CNS depressants can be expected to present as exaggerations of the pharmacological effects noted in preclinical testing.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 4 Einträge

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

Zopiclone

DILI Positive

DOI:10.1016/j.drudis.2019.09.022

Sicherheitsdaten

wgk
3
ridadr
UN 1648 3 / PGII
hs_code
2933990099
RTECS-Nr.
TL1425000
risk_code
20/21/22-36/37/38-62-36-11
Toxizität
mouse,LD50,intramuscular,541mg/kg (541mg/kg),LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSIONBEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY),Oyo Yakuri. Pharmacometrics. Vol. 26, Pg. 935, 1983.
hazard_code
Xn,Xi,F
safety_code
26-36-36/37-16
Speicherklasse
3 - Flammable liquids
Hazard Classifications
Acute Tox. 4 DermalAcute Tox. 4 InhalationAcute Tox. 4 OralEye Irrit. 2Flam. Liq. 2

Extensively metabolized in the liver via decarboxylation (major pathway), demethylation, and side chain oxidation. Metabolites include an N-oxide derivative (weakly active; approximately 12% of a dose) and an N-desmethyl metabolite (inactive; approximately 16%). Approximately 50% of a dose is converted to other inactive metabolites via decarboxylation. Hepatic microsomal enzymes are apparently not involved in zopiclone clearance. Half Life: Elimination half life is approximately 5 hours (range 3.8 to 6.5 hours) and is prolonged to 11.9 hours in patients with hepatic insufficiency.

MeSH Pharmacological ClassificationDrugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety.
Absorption, Distribution and ExcretionRapidly absorbed following oral administration.
Cellular LocationsCytoplasm

Verwendung und Herstellung

Uses · 2 Einträge

Use (kg; approx.) in Germany (2009): >500

For the short-term treatment of insomnia.

Use ClassificationPharmaceuticals
Anwendungen · 2 Einträge

BeschreibungZopiclone is an effective hypnotic agent with a short duration of action. Although it interacts with the benzodiazepine receptor complex, it is reported to have minimal effects on memory, little synergy with alcohol, and low abuse potential.

VerwendenCyclopyrrolone member of a family of non-benzodiazepine GABAA receptor agonists. This is a controlled substance (depressant) in the US but not in Canada. Sedative, hypnotic

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

5-Chlor-2-pyridylaminErythromycin-2'-propanoat-dodecylsulfatPyrazinN,N-DimethylformamidPyrrol1-MethylpiperazinTrichlormethanPiperazin1,4-DioxanKaliumtetrahydroboratEssigsureAnhydrous pyridineDiisopropyletherNatriumhydroxidNatriumhydrid(R)-Zopiclone6-(5-Chloro-pyridin-2-yl)-7-phenoxycarbonyloxy-6,7-dihydro-pyrrolo3,4-bpyrazin-5-oneEszopiclone

Ergänzende Hinweise

DefinitionChEBI: A pyrrolo[3,4-b]pyrazine compound having a 4-methylpiperazine-1-carboxyl group at the 5-position, a 5-chloropyridin-2-yl group at the 6-position and an oxo-substituent at the 7-position.